Dr. Shen is a seasoned biotech executive and drug developer with more than 20 years of experience advancing innovative therapies in oncology and rare diseases from discovery through commercialization. She brings extensive expertise in translational medicine, clinical development, and regulatory affairs. Dr. Shen currently serves as Vice President of Strategic Innovation Leaders at Mass General Brigham (MGB) Innovation and Head of Regulatory at the MGB Gene and Cell Therapy Institute. Before joining MGB, Dr. Shen served as Chief Medical Officer for several successful venture-backed biotech companies, leading multiple novel therapies into clinic, including CART-ddBCMA (anito-cel). During her tenure at Novartis, Dr. Shen was extensively involved with in-licensing U Penn’s CAR-T technology, and led the clinical team that designed and launched industry’s first multi-site registrational CAR-T trial, resulting in the landmark FDA approval of Kymriah.